All In Biotech

Drug Trial Radar · NCT07834515

Phase 1b Clinical Study in Patients With Active Ulcerative Colitis

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy Signal of TP-317 in Patients With Active Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

Jul 29, 2027

Study completion Aug 29, 2027

Sponsor

Lead sponsor
Thetis Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Sep 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Purpose of study is to evaluate the safety, tolerability, pharmacokinetics of TP317 vs. placebo in adults with active ulcerative colitis. Participants will be randomly assigned to receive either daily oral tablets (8 tablets) of TP317 (80 mg) or an identical placebo pill. Study will include 2 colonoscopies, daily dosing (including at home and in clinic), safety assessments, diary and questionnaire completion and 5 in clinic visits.

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • TP317Drug

    8 tablets (80 mg) of TP317 oral tablets, taken once daily under fasted conditions for a total duration of 12 weeks.

  • Matching placeboDrug

    Matching oral tablet containing no active ingredients, taken once daily for 12 weeks to maintain blinding.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of TP317Time frame: Collected from baseline through Week 12
  2. Safety of TP317Time frame: Baseline through Week 12
  3. Safety of TP317Time frame: Baseline through Week 12
  4. Safety of TP317Time frame: Baseline to Week 12
  5. Pharmacokinetics of TP317Time frame: Baseline through Week 12
  6. Pharmacokinetics of TP317Time frame: Baseline through Week 12
  7. Pharmacokinetics of TP317Time frame: Baseline through Week 12
  8. Pharmacokinetics of TP317Time frame: Baseline through Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.